Harold J. Burstein։ Big Year for Long-Term Endocrine Therapy in Breast Cancer

Harold J. Burstein, Breast cancer specialist and professor at Dana-Farber Cancer Institute and Harvard Medical School, shared a post on X:

“It has been a big year for long-term follow-up of adjuvant endocrine prescription in breast cancer.

1. Extended therapy. Overview shows AI treatment 5 -> 10 years lowers recurrence and distant recurrence. Esp in N+ and patients given tamoxifen in years 0-5.
2. Also, at ASCO, we saw long term benefit (15 year follow up) for ovarian function suppression in premenopausal women, esp. those younger (< 35/40), with higher stage cancers and higher grade cancers.
3. No denying the side effects of these treatments, but they do work!”

Title: Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy

Journal: The Lancet

Authors: Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

Read the full article.

More posts featuring Harold J. Burstein on OncoDaily.